Vir Biotechnology stock jumps 60%+ premarket on Astellas deal, upbeat VIR-5500 data
New York, Feb 24, 2026, 05:28 EST — Premarket Shares of Vir Biotechnology soared roughly 64% in Tuesday’s premarket session, following news of its collaboration with Japan’s Astellas Pharma and new early-stage results from its prostate cancer program, VIR-5500.